Novo’s struggles to keep up with demand also allowed compounding pharmacies to step in, chipping away at its market share and making 2025 one of its toughest years yet.
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?
